Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Xeris Biopharma Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was €1,307.9 Mil.
Xeris Biopharma Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €33.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings EV-to-EBIT Related Terms
Xeris Biopharma Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2B30 vs HROW, PRGO, PAHC: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's EV-to-EBIT falls into.
Xeris Biopharma Holdings's current Enterprise Value is €1,498.4 Mil.
Xeris Biopharma Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €33.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings (FRA:2B30) has a EV-to-EBIT of 44.56 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xeris Biopharma Holdings and its competitors. According to the industry distribution chart, Xeris Biopharma Holdings ranks #566 out of 691 companies in the Drug Manufacturers industry, placing it in the top 81.9%.
Is Xeris Biopharma Holdings' EV-to-EBIT too high?
Xeris Biopharma Holdings' current EV-to-EBIT is 44.56. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Xeris Biopharma Holdings' value of 44.56 is 182.6% above this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #566 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' EV-to-EBIT compare to HROW and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #566 out of 691 companies for EV-to-EBIT. This places Xeris Biopharma Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.77. Xeris Biopharma Holdings' value of 44.56 is 182.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current EV-to-EBIT of 44.56 is 182.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current EV-to-EBIT is 44.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (FRA:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.58, compared to a current price of €7.36 — trading 60.7% above its estimated fair value. The current EV-to-EBIT is 44.56 and 182.6% above the Drug Manufacturers industry median of 15.77. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Xeris Biopharma Holdings (FRA:2B30), the current EV-to-EBIT is 44.56 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (FRA:2B30) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of €7.36 is trading 60.7% above its estimated GF Value™ of €4.58.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for FRA:2B30:
EV-to-EBIT: 44.56
GF Value™: €4.58 vs. price of €7.36 (60.7% above fair value)
Industry Position: 182.6% above the Drug Manufacturers median (#566 of 691)
No single metric tells the full story. See the FRA:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score
Get the complete analysis for FRA:2B30
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2B30 has been successfully added to your 
